The new policy expands coverage to more Medicare beneficiaries using insulin to treat diabetes, as well as people who need help managing hypoglycemia, and removes the prior requirement of multiple daily insulin injections.
Abbott and Dexcom are praising a new Medicare policy that expands coverage of continuous glucose monitoring (CGM) for people with diabetes who use insulin and for people who struggle with hypoglycemia that may cause dizziness or unconsciousness.
The Centers for Medicare and Medicaid Service enacted the new local coverage determination on 16 April.
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
